| New York nephrologist gets tangled up with an insider trading case based on nephrotic syndrome drug. |
|
| NY Times: Doctor 1 talked to the money manager in June 2010 about an unpublished study of an obscure drug, according to the complaint filed by the state’s securities regulator. The hedge fund bought more than $800,000 in stock in Questcor, the company whose sole product was that drug, and saw its value soar. |